VDR Activation Suppresses Pancreatic Cancer Metastasis Through Inhibition of the ERK Signaling Pathway

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The vitamin D receptor (VDR) is linked to tumor progression, but its specific role in pancreatic ductal adenocarcinoma (PDAC) metastasis is not well understood.
• Understanding VDR's function in PDAC is crucial for developing targeted therapies against cancer spread.

Purpose of the Study:

• To investigate the functional role of the vitamin D receptor (VDR) in the metastatic process of pancreatic ductal adenocarcinoma (PDAC).
• To elucidate the molecular mechanisms underlying VDR's effect on PDAC metastasis and identify potential therapeutic targets.

Main Methods:

• Utilized pharmacological VDR activation (calcipotriol) and genetic manipulation (gain- and loss-of-function) in PDAC models.
• Performed transcriptomic profiling (RNA sequencing) to analyze gene expression changes upon VDR modulation.
• Employed in vitro assays for cell migration and invasion, and in vivo lung colonization assays to assess metastatic potential.

Main Results:

• VDR activation by calcipotriol inhibited PDAC cell migration and invasion without affecting proliferation.
• Genetic or pharmacological VDR inhibition significantly enhanced PDAC metastatic phenotypes.
• VDR activation altered MAPK/ERK signaling, and ERK inhibition counteracted VDR loss-induced pro-metastatic effects.
• VDR deficiency markedly promoted pulmonary metastatic colonization in vivo.

Conclusions:

• The vitamin D receptor (VDR) acts as a suppressor of pancreatic ductal adenocarcinoma (PDAC) metastasis.
• A novel VDR-ERK regulatory axis was identified, highlighting its importance in controlling PDAC cell metastatic colonization.
• Targeting the VDR-ERK pathway presents a potential therapeutic strategy to inhibit pancreatic cancer progression and metastasis.